Skip to main content

Table 2 Comparison of baseline characteristics of patients in the ETNA-AF-Europe registry and ENGAGE AF-TIMI 48 trial

From: Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

 

ETNA-AF-Europe N = 13,638

ENGAGE AF-TIMI 48a Corresponding ETNA-AF countriesb N = 2123

Age (y), mean (SD)

73.6 (9.52)

72.7 (8.09)

By age sub-groups, n (%)

  < 65 years

2096 (15.4)

344 (16.2)

 65–75 years

4598 (33.7)

764 (36.0)

  ≥ 75 years

6939 (50.9)

1015 (47.8)

Male, %

56.6

62.4

BMI (kg/m2), mean (SD)

28.1 (5.14)

29.8 (5.39)

Weight (kg), mean (SD)

81.0 (17.34)

85.4 (17.47)

eCrCl (mL/min), mean (SD)

69.4 (24.23)

75.5 (28.96)

CHADS2, mean (SD)

1.7 (1.07)

2.8 (0.93)

CHA2DS2-VASc, calculated, mean (SD)

3.1 (1.40)

4.2 (1.31)

HAS-BLED, mean (SD)

2.6 (1.13)

1.6 (0.92)

Hypertension, %

76.9

92.4

Diabetes, %

21.9

39.1

Myocardial infarction, %

4.3

2.9

Ischaemic stroke, %

5.9

15.5

Transient ischaemic attack, %

3.3

11.9

Congestive heart failure, %

5.8

48.2

Paroxysmal AF, %

53.6

26.6

Persistent AF, %

24.4

24.1

Permanent AF, %

19.6

49.4

Renal disease (including dialysis), %

27.0

11.9

  1. amITT
  2. bBelgium, Switzerland, Germany, Spain, United Kingdom, Italy, Netherlands, Portugal
  3. % values are based on non-missing data
  4. AF atrial fibrillation, BMI body mass index, CHADS2 Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke (double weight), eCrCl estimated creatinine clearance (Cockcroft-Gault), ENGAGE AF-TIMI 48 study Effective aNticoaGulAtion with Factor Xa next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48, ETNA-AF Edoxaban Treatment in routine cliNical prActice, mITT modified intent-to-treat, SD standard deviation